UW madison
UW School of Medicine and Public Health
Carbone Cancer Center

Shigeki Miyamoto, Ph.D.

Shigeki Miyamoto
Professor of Oncology
Developmental Therapeutics Program Leader - UW Carbone Cancer Center

B.A., 1985, Biochemistry/Molecular Biology, University of California-Santa Cruz
, 1990, Cancer Research/Endocrinology, University of California-Berkeley
Postdoctoral research: Salk Institute, San Diego

6159 Wisconsin Institutes for Medical Research
Office - (608) 262-9281; Lab - (608) 265-8595
Research Description: 

Over the last two decades, the Miyamoto lab has pursued a variety of research interests centered around cell signaling and asked "what happens when cells are no longer able to communicate effectively?" Most of the current research is focused on understanding the NF-κB signaling pathway as a model. Our lab, and others, have shown that NF-κB is key in promoting cell survival (anti-apoptotic), normal immune system development, stress response, early embryonic development, cell adhesion, and tumor metastasis.

With regard to the NF-κB model, our lab has two overarching research interests. First, we are interested in characterizing how nuclear stress conditions, such as DNA damage, induce signaling events in the cytoplasm. Second, we are interested in how cancer cells use signaling mechanisms for their growth and survival advantages to evade anticancer drug effects.  We are currently focusing on the NF-κB signaling system as an important paradigm to increase our understanding of these processes.

Selected Recent Publications: 


Babaei M, Liu Y, Wuerzberger-Davis SM, McCaslin EZ, DiRusso CJ, Yeo AT, Kagermazova L, Miyamoto S, Gilmore TD. CRISPR/Cas9-based editing of a sensitive transcriptional regulatory element to achieve cell type-specific knockdown of the NEMO scaffold protein. PLoS One. 2019 Sep 25;14(9):e0222588. doi: 10.1371/journal.pone.0222588. eCollection 2019. PubMed PMID: 31553754.; PubMed Central PMCID: PMC6760803

Lung DK, Warrick JW, Hematti P, Callander NS, Mark CJ, Miyamoto S, Alarid ET. Bone marrow stromal cells transcriptionally repress ESR1 but cannot overcome constitutive ESR1 mutant activity. Endocrinology. 2019 Jul 25. pii: en.2019-00299. doi: 10.1210/en.2019-00299. [Epub ahead of print] PubMed PMID: 31504407.


Huynh M, Pak C, Markovina S, Callander NS, Chng KS, Wuerzberger-Davis SM, Bakshi DD, Kink JA, Hematti P, Hope C, Asimakopoulos F, Rui L, Miyamoto S. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma. J Biol Chem. 2018 Feb 16;293(7):2452-2465. doi: 10.1074/jbc.RA117.000667. Epub 2017 Dec 26. PubMed PMID: 29279332; PubMed Central PMCID: PMC5818187.


Hope C, Emmerich PB, Papadas A, Pagenkopf A, Matkowskyj KA, Van De Hey DR, Payne SN, Clipson L, Callander NS, Hematti P, Miyamoto S, Johnson MG, Deming DA, Asimakopoulos F. Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. J Immunol. 2017 Sep 1;199(5):1933-1941. doi: 10.4049/jimmunol.1700529. Epub 2017 Jul 28. PubMed PMID: 28754680; PubMed Central PMCID: PMC5568487.

Zhu F, Hwang B, Miyamoto S, Rui L. Nuclear Import of JAK1 Is Mediated by a Classical NLS and Is Required for Survival of Diffuse Large B-cell Lymphoma. Mol Cancer Res. 2017 Mar;15(3):348-357. doi: 10.1158/1541-7786.MCR-16-0344. PubMed PMID: 28031410; PubMed Central PMCID: PMC5473959.


Hope C, Foulcer S, Jagodinsky J, Chen SX, Jensen JL, Patel S, Leith C, Maroulakou I, Callander N, Miyamoto S, Hematti P, Apte SS, Asimakopoulos F. Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood. 2016 Aug 4;128(5):680-5. doi: 10.1182/blood-2016-03-705780. Epub 2016 Jun 3. PubMed PMID: 27259980; PubMed Central PMCID: PMC4974200.

Li Y, Bouchlaka MN, Wolff J, Grindle KM, Lu L, Qian S, Zhong X, Pflum N, Jobin P, Kahl BS, Eickhoff JC, Wuerzberger-Davis SM, Miyamoto S, Thomas CJ, Yang DT, Capitini CM, Rui L. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. Oncogene. 2016 Dec 1;35(48):6223-6234. doi: 10.1038/onc.2016.155. PubMed PMID: 27157620; PubMed Central PMCID: PMC5102814.


Helzer KT, Hooper C, Miyamoto S, Alarid ET. Ubiquitylation of nuclear receptors: new linkages and therapeutic implications. J Mol Endocrinol. 2015 Jun;54(3):R151-67. doi: 10.1530/JME-14-0308. Epub 2015 May 5. Review. PubMed PMID: 25943391; PubMed Central PMCID: PMC4457637.

Hwang B, McCool K, Wan J, Wuerzberger-Davis SM, Young EW, Choi EY, Cingolani G, Weaver BA, Miyamoto S. IPO3-mediated Nonclassical Nuclear Import of NF-κB Essential Modulator (NEMO) Drives DNA Damage-dependent NF-κB Activation. J Biol Chem. 2015 Jul 17;290(29):17967-84. doi: 10.1074/jbc.M115.645960. Epub 2015 Jun 9. PubMed PMID: 26060253; PubMed Central PMCID: PMC4505044.

Hwang B, Phan FP, McCool K, Choi EY, You J, Johnson A, Audhya A, Miyamoto S. Quantification of cellular NEMO content and its impact on NF-κB activation by genotoxic stress. PLoS One. 2015 Mar 5;10(3):e0116374. doi: 10.1371/journal.pone.0116374. eCollection 2015. PubMed PMID: 25742655; PubMed Central PMCID: PMC4350935.

Jackson SS, Miyamoto S. Dissecting NF-κB signaling induced by genotoxic agents via genetic complementation of NEMO-deficient 1.3E2 cells. Methods Mol Biol. 2015;1280:197-215. doi: 10.1007/978-1-4939-2422-6_11. PubMed PMID: 25736750; PubMed Central PMCID: Policy Exempt – book chapter.

Jackson SS, Oberley C, Hooper CP, Grindle K, Wuerzberger-Davis S, Wolff J, McCool K, Rui L, Miyamoto S. Withaferin A disrupts ubiquitin-based NEMO reorganization induced by canonical NF-κB signaling. Exp Cell Res. 2015 Feb 1;331(1):58-72. doi: 10.1016/j.yexcr.2014.09.034. Epub 2014 Oct 7. PubMed PMID: 25304104; PubMed Central PMCID: PMC4302062.

Jensen JL, Rakhmilevich A, Heninger E, Broman AT, Hope C, Phan F, Miyamoto S, Maroulakou I, Callander N, Hematti P, Chesi M, Bergsagel PL, Sondel P, Asimakopoulos F. Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunol Res. 2015 Aug;3(8):881-90. doi: 10.1158/2326-6066.CIR-15-0025-T. Epub 2015 May 4. PubMed PMID: 25941352; PubMed Central PMCID: PMC4527950.

Kimble J, Bement WM, Chang Q, Cox BL, Drinkwater NR, Gourse RL, Hoskins AA, Huttenlocher A, Kreeger PK, Lambert PF, Mailick MR, Miyamoto S, Moss RL, O'Connor-Giles KM, Roopra A, Saha K, Seidel HS. Strategies from UW-Madison for rescuing biomedical research in the US. Elife. 2015 Jun 30;4:e09305. doi: 10.7554/eLife.09305. PubMed PMID: 26122792; PubMed Central PMCID: PMC4484056.

Pak C, Callander NS, Young EW, Titz B, Kim K, Saha S, Chng K, Asimakopoulos F, Beebe DJ, Miyamoto S. MicroC3: an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. Integr Biol (Camb). 2015 Jun;7(6):643-54. doi: 10.1039/c5ib00071h. Epub 2015 May 22. PubMed PMID: 25998180; PubMed Central PMCID: PMC4476551.


Berry, S. M., Chin, E. N., Jackson, S. S., Strotman, L. N., Goel, M., Thompson, N. E., Alexander, C. M., Miyamoto, S., Burgess, R. R., and Beebe, D. J.  Weak Protein-Protein Interactions Revealed by Immiscible Filtration Assisted by Surface Tension.  Anal. Biochem., 447: 133-140, 2014.

Callander, N., Markovina, S., Eickhoff, J., Hutson, P., Campbell, T., Hematti, P., Go, R., Hegeman, R., Longo, W., Williams, E., Asimakopoulos, F., and Miyamoto, S.  Acetyl-l-Carnitine (ALCAR) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients with Relapsed or Refractory Multiple Myeloma Treated with Bortezomib, Doxorubicin and Low-Dose Dexamethasone:  A Study from the Wisconsin Oncology Network. Cancer Chemother. Pharmacol., 74(4):  875-882, 2014.

Hooper, C., Jackson, S. S., Coughlin, E. E., Coon, J. J., and Miyamoto, S.  Covalent Modification of the NF-κB Essential Modulator (NEMO) by a Chemical Compound Can Regulate Its Ubiquitin Binding Properties in Vitro.  J. Biol. Chem., 289(48): 33161-33174, 2014.

Hope, C., Ollar, S. J., Heninger, E., Hebron, E., Jensen, J. L., Kim, J., Maroulakou, I., Miyamoto, S., Leith, C., Yang, D. T., Callander, N., Hematti, P., Chesi, M., Bergsagel, P. L., and Asimakopoulos, F.  TPL2 Kinase Regulates the Inflammatory Milieu of the Myeloma Niche.  Blood, 123(21): 3305-3315, 2014.

Hsu, K.-T., Yu, X.-M., Audhya, A. W., Jaume, J. C., Lloyd, R. V., Miyamoto, S., Prolla, T. A., and Chen, H.  Novel Approaches in Anaplastic Thyroid Cancer Therapy.  Oncologist, 19: 1148-1155, 2014.

Shin, E. M., Hay, H. S., Lee, M. H., Goh, J. N., Tan, T. Z., Sen, Y. P., Lim, S. W., Yousef, E. M., Ong, H. T., Thike, A. A., Kong, X., Wu, Z., Mendoz, E., Sun, W., Salto-Tellez, M., Lim, C. T., Lobie, P. E., Lim, Y. P., Yap, C. T., Zeng, Q., Sethi, G., Lee, M. B., Tan, P., Goh, B. C., Miller, L. D., Thiery, J. P., Zhu, T., Gaboury, L., Tan, P. H., Hui, K. M., Yip, C. W.-C., Miyamoto, S., Kumar, A. P., and Tergaonkar, V.  DEAD-Box Helicase DP103 Defines Metastatic Potential of Human Breast Cancers.  J. Clin. Invest., 124(9):  3807-3824, 2014.

Yang, B., Wagner, J., Damaschke, N., Yao, T., Wuerzberger-Davis, S. M., Lee, M.-H., Svaren, J., Miyamoto, S., and Jarrard, D. F.  A Novel Pathway Links Oxidative Stress to Loss of Insulin Growth Factor-2 (IGF2) Imprinting through NF-κB Activation.  PLoS One, 9(2):e88052, 2014.


Hebron, E., Hope, C., Kim, J., Jensen, J. L., Flanagan, C., Bhatia, N., Maroulakou, I., Mitsiades, C., Miyamoto, S., Callander, N., Hematti, P., and Asimakopoulos, F.  MAP3K8 Kinase Regulates Myeloma Growth by Cell-Autonomous and Non-Autonomous Mechanisms Involving Myeloma-Associated Monocytes/Macrophages.  Brit. J. Haematol., 160(6): 779-784, 2013.

Jackson, S. S., Coughlin, E. E., Coon, J. J., and Miyamoto, S.  Identifying Post-Translational Modifications of NEMO by Tandem Mass Spectrometry After High Affinity Purification.  Prot. Expr. Purif., 92(1): 48-53, 2013.

Mulero, M. C., Ferres-Marco, D., Islam, A., Margalef, P., Pecoraro, M., Toll, A., Drechsel, N., Charneco, C., Davis, S., Bellora, N., Gallardo, F., López-Arribillaga, E., Asensio-Juan, E., Rodilla, V., González, J., Iglesias, M., Shih, V., Albà, M. M., Di Croce, L., Hoffmann, A., Miyamoto, S., Villà-Freixa, J., López-Bigas, N., Keyes, W. M., Domínguez, M., Bigas, A., and Espinosa, L.  Chromatin-Bound IκBα Regulates a Subset of Polycomb Target Genes in Differentiation and Cancer.  Cancer Cell, 24(2): 151-166, 2013.

Pak, C., and Miyamoto, S.  A New Alpha in Line Between KRAS and NF-κB Activation?  Cancer Discov., 3(6):  613-615, 2013.


McCool, K. W., and Miyamoto, S.  DNA Damage-dependent NF-κB Activation:  NEMO Turns Nuclear Signaling Inside Out.  Immunol. Rev., 246:  311-326, 2012.

Young, E. W. K., Pak, C., Kahl, B. S., Yang, D. T., Callander, N. S., Miyamoto, S., and Beebe, D. J.  Microscale Functional Cytomics for Studying Hematologic Cancers.  Blood, 119: e76-e85, 2012.

Perform a PubMed search for additional Miyamoto publications

National Committees: 

Member, National Institutes of Health Tumor Microenvironment Study Section, 2011-2017

Donate Now